PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419053
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419053
Vaccine Adjuvants Market size was valued at USD 712.5 Million in 2022, expanding at a CAGR of 7.2% from 2023 to 2030.
Vaccine adjuvants are components integrated into vaccines to heighten the body's immune response triggered by the vaccine's antigen, which stimulates the immune system. These adjuvants function by amplifying the body's immune reaction, thereby enhancing the vaccine's effectiveness by bolstering the immune response and often permitting the use of smaller antigen amounts. They can induce a more robust and longer-lasting immune response, thereby elevating defense against the targeted disease. Adjuvants also aid in enhancing vaccine efficacy for specific populations, such as the elderly or individuals with compromised immune systems. Diverse adjuvant types encompass aluminum salts (like aluminum hydroxide or aluminum phosphate), oil-in-water emulsions (such as MF59 or AS03), toll-like receptor agonists, among others. Adjuvants are pivotal in vaccine development, facilitating the creation of more potent vaccines against various infectious diseases and augmenting overall vaccine effectiveness and the endurance of immune responses.
The prevalence of infectious diseases like influenza, tuberculosis, cholera, polio, measles, malaria, and HIV has escalated. According to the WHO, TB ranked as the 13th leading cause of death globally and stood as the second-leading infectious cause of death after COVID-19 in 2021, with almost 1.6 million reported deaths worldwide, including 187,000 individuals with HIV. The surge in cases has put immense pressure on vaccine production, as an increased number of vaccines are necessary to combat such contagious diseases, consequently heightening the demand for adjuvants.
The Global Vaccine Adjuvants Market is segmented on the basis of Product Type, Application, Usage Type, Disease Area, and Region.
The market is divided into eight categories based on product type: Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP) and Others. Based on product categorization, the adjuvant emulsions segment is forecasted to uphold its leading position during he forecat period. This is primarily accredited to the escalating prevalence of communicable diseases, propelling the usage of emulsion adjuvants in vaccines and consequently nurturing the expansion of this specific segment.
The market is divided into two categories based on application: research and commercial. The commercial sector dominates the market and is likely to maintain its dominance during the forecast period. With the rise in infectious diseases and ongoing public health concerns globally, there's a growing need for effective vaccines. Adjuvants contribute significantly to developing vaccines that offer improved protection, enabling healthcare systems to expand vaccination programs, especially in regions where there is a high prevalence of infectious diseases.
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
The market for vaccine adjuvants is currently undergoing strategic advancements directed at enhancing both the efficacy and safety of vaccines. These innovations concentrate on pioneering adjuvant formulations and delivery systems, aiming to intensify immune responses while upholding safety standards. Significant research and development endeavors are directed towards tailoring adjuvants specifically for distinct vaccines, thereby augmenting their effectiveness across diverse demographic groups. Moreover, collaborations among pharmaceutical firms, research institutions, and regulatory bodies are propelling the development and validation of adjuvants, especially for emerging infectious diseases and challenging pathogens. Market dynamics center around regulatory adherence, cost-efficiency, and scalability, setting the stage for transformative adjuvant technologies that fortify vaccine responses and contribute to global public health improvements.
In January 2023, Elicio Therapeutics, specializing in lymph node-targeted adjuvants as well as vaccines for violent cancers along with infectious illnesses, finalized a union agreement with Angion Biomedica Corp. The focus lies on advancing Elicio's exclusive lymph node-targeting Amphiphile expertise to progress immunotherapies, primarily concentrating on ELI-002, a therapeutic cancer vaccine aimed at mKRAS-driven tumors.
In November 2022, Hubro Therapeutics AS acquired the GM-CSF vaccine adjuvant from Targovax ASA through an asset purchase agreement, involving a cash payment of NOK10 million. Hubro is continuing the development of GM-CSF as an adjuvant for its range of innovative cancer vaccines in its pipeline.
The scope of this report covers the market by its major segments, which include as follows: